Related Experiment Videos
Clinical experience with sodium valproate in children
Insights
Sodium valproate effectively controlled severe epilepsy in 71% of children. This epilepsy medication showed good results for various seizure types with minimal side effects, though cost is a barrier.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
Background:
- Recurrent epileptic seizures in children pose significant management challenges.
- Identifying effective and well-tolerated anti-epileptic drugs is crucial for pediatric care.
Purpose of the Study:
- To evaluate the efficacy and tolerability of sodium valproate in children with severe, recurrent epileptic seizures.
- To assess the effectiveness of sodium valproate across different epilepsy syndromes.
Main Methods:
- A sample of 62 children with severe recurrent epileptic seizures was treated with sodium valproate (Epilim).
- Efficacy was assessed by seizure control, and concurrent anti-convulsant use was recorded.
- Side-effects were monitored throughout the study period.
Main Results:
- Sodium valproate achieved good seizure control in 44 (71%) of the children.
- The medication was most effective for petit mal seizures but also showed benefits in grand mal, psychomotor, and myoclonic seizures.
- Most children required minimal or no additional anti-convulsant medication, and side-effects were infrequent and mild.
Conclusions:
- Sodium valproate is an effective and generally well-tolerated treatment for severe childhood epilepsy.
- Its broad efficacy across seizure types makes it a valuable therapeutic option.
- The primary limitation for wider use in South Africa is the high cost of the medication.
Abstract:
Good control was achieved with sodium valproate (Epilim) in 44 (71%) of a sample of 62 children with severe recurrent epileptic seizures. The medication was most effective in the control of petit mal; good results, however, were also achieved in some patients with previously poorly controlled grand mal epilepsy and psychomotor and myoclonic seizures. Twenty children required no other anti-convulsant and 28 required only one other. Side-effects were infrequent and mild. Only the high cost of sodium valproate in South Africa precludes its more general use in childhood epilepsy.